# International Prognostic Index (IPI)

Source: https://onco.cc/terms/ipi-score/  
OnCo record `ipi-score` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A five-point score (age, stage, performance status, LDH, extranodal sites) that predicts how risky a lymphoma is before treatment.

## Summary

The International Prognostic Index is a five-point score for aggressive lymphoma that counts age, stage, performance status, LDH and extranodal involvement, and is calculated before treatment begins. Scores of 0 to 1 are low risk, 2 low-intermediate, 3 high-intermediate and 4 to 5 high risk. In diffuse large B-cell lymphoma the IPI defines trial eligibility, with POLARIX enrolling patients scoring 2 to 5 and frontMIND those scoring 3 to 5, and it frames the expected outcome of R-CHOP, which is far better at the low end of the scale than at the high end in the rituximab era. Readers meet it on the DLBCL page and in those two trial records.

## Fields

- Kind: Term
- Last checked: 2026-09-07
- Also known as: IPI; IPI score; NCCN-IPI; CNS-IPI; R-IPI; revised IPI; age-adjusted IPI; aaIPI

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/International_Prognostic_Index
- Wikipedia: https://en.wikipedia.org/wiki/International_Prognostic_Index

## Connected records

- cancers: [ALK-negative anaplastic large cell lymphoma](https://onco.cc/cancers/alk-negative-anaplastic-large-cell-lymphoma/), [ALK-positive anaplastic large cell lymphoma](https://onco.cc/cancers/alk-positive-anaplastic-large-cell-lymphoma/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [High-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit lymphoma)](https://onco.cc/cancers/high-grade-b-cell-lymphoma-myc-bcl2/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Primary large B-cell lymphoma of the testis](https://onco.cc/cancers/primary-testicular-lymphoma/), [T-cell/histiocyte-rich large B-cell lymphoma](https://onco.cc/cancers/t-cell-histiocyte-rich-large-b-cell-lymphoma/)
- trials: [Alliance/CALGB 50303](https://onco.cc/trials/calgb-50303/), [FLYER](https://onco.cc/trials/flyer/), [frontMIND](https://onco.cc/trials/frontmind/), [POLARIX](https://onco.cc/trials/polarix/), [REMARC](https://onco.cc/trials/remarc/)
- terms: [CNS prophylaxis in aggressive B-cell lymphoma, and the evidence against it](https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/), [FLIPI, FLIPI2 and POD24 (follicular lymphoma risk)](https://onco.cc/terms/flipi/), [MIPI (Mantle Cell Lymphoma International Prognostic Index)](https://onco.cc/terms/mipi/), [Nodal and extranodal lymphoma](https://onco.cc/terms/lymphoma-nodal-versus-extranodal/), [Prognostic Index for T-cell lymphoma (PIT)](https://onco.cc/terms/lymphoma-pit-score/)
- key papers: [Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray](https://onco.cc/key-papers/paper-hans-immunohistochemistry-cell-of-origin-dlbcl-blood-2004/), [Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes](https://onco.cc/key-papers/paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018/), [Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma](https://onco.cc/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/), [The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma](https://onco.cc/key-papers/paper-rosenwald-molecular-profiling-dlbcl-nejm-2002/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/ipi-score.json